Michelle Lynn Hall

General Partner at Entrée Capital

Speaker

Michelle Lynn Hall is a biotechnology executive, scientist, and venture investor with extensive expertise in small molecules, biologics, RNA therapeutics, gene editing, and nonviral delivery systems. She held senior leadership positions at Eli Lilly, where she built and led interdisciplinary teams integrating computation, automation, and experimental science. Earlier in her career, she worked at Moderna, Schrödinger, and Novartis in scientific and technical roles focused on computational chemistry, RNA therapeutics, and nanomedicine. Michelle is the co-founder and general partner of Entrée Bio, where she concentrates on company creation and early-stage investments at the crossroads of AI, data-driven biology, and next-generation medicines.